Very, very strong endorsement of the anti-VEGF therapy for AMD and DME.
If I take (my) relation of the deal versus market value (1:10), than +$800M Eyetech's Macugen deal speak for itself.
Guys, speed up with VEGF-trap!
Miljenko
Pfizer To Pay Eyetech $100 Million In Deal
Wednesday December 18, 6:23 am ET
NEW YORK -(Dow Jones)- Pfizer Inc. (NYSE:PFE - News) and Eyetech Pharmaceuticals Inc. signed an agreement to develop and sell Eyetech's Macugen, a potential treatment for age-related macular degeneration and diabetic macular edema, which both cause blindness.
In a press release Wednesday, Pfizer said it will make initial payments of $ 100 million, with $195 million in possible milestone payments, based on gaining regulatory approvals.
Privately held Eyetech also has the potential to receive up to $450 million in additional milestone payments, based on successful commercialization and sales levels.
Pfizer, which reported revenue of $25.18 billion for the nine months ended Sept. 29, will fund the majority of the ongoing development for the drug used in these indications. |
